Neamine

Identification

Name
Neamine
Accession Number
DB04808
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Dekamycin V
  • Nebramycin X
  • Negamicin
  • Neomycin A
Categories
UNII
5981U00LY0
CAS number
3947-65-7
Weight
Average: 322.358
Monoisotopic: 322.185234584
Chemical Formula
C12H26N4O6
InChI Key
SYJXFKPQNSDJLI-HKEUSBCWSA-N
InChI
InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1
IUPAC Name
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy}oxane-3,4-diol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Neamine.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Neamine.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Withdrawn
AlcuroniumNeamine may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidNeamine may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Neamine can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Neamine can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Neamine.Approved, Investigational
AmpicillinThe serum concentration of Neamine can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Neamine can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumNeamine may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateNeamine may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Neamine can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Neamine can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Neamine can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Neamine can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Neamine can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Neamine can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Botulinum Toxin Type ANeamine may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BNeamine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neamine.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Neamine.Approved
CarbenicillinThe serum concentration of Neamine can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Neamine can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinNeamine may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Neamine can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
CisatracuriumNeamine may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateNeamine may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Neamine.Approved
Clodronic AcidNeamine may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Neamine can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateNeamine may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Neamine can be decreased when it is combined with Cyclacillin.Approved
CyclosporineNeamine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Neamine.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
DecamethoniumNeamine may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Neamine.Approved
DiclofenacDiclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Neamine can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Neamine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Neamine.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Neamine.Approved
Domoic AcidNeamine may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideNeamine may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Neamine can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neamine.Approved
EtanerceptEtanercept may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Etidronic acidNeamine may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Neamine can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Neamine which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Neamine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Neamine.Approved, Vet Approved
GallamineNeamine may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideNeamine may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Neamine.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
IbandronateNeamine may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Neamine.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Neamine.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
MecamylamineNeamine may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Neamine can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Neamine can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Neamine.Experimental
MetocurineNeamine may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideNeamine may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Neamine can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumNeamine may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Neamine can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinNeamine may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Neamine.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Neamine which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Neamine.Approved
OxacillinThe serum concentration of Neamine can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Withdrawn
PamidronateNeamine may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumNeamine may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Neamine can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Neamine can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Neamine.Experimental
PhenoxymethylpenicillinThe serum concentration of Neamine can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
PipecuroniumNeamine may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Neamine can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Neamine.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Neamine can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Neamine can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Neamine can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Neamine can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Neamine.Experimental
PTC299PTC299 may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
PyrantelNeamine may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumNeamine may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateNeamine may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumNeamine may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
SuccinylcholineNeamine may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Neamine can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Neamine can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Neamine can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Neamine can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Neamine can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateNeamine may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateNeamine may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Neamine can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Neamine which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Neamine can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidNeamine may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Neamine which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Neamine.Approved
TranilastTranilast may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational
TubocurarineNeamine may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Neamine.Approved
VecuroniumNeamine may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Neamine which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidNeamine may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Neamine which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, "1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof." U.S. Patent US4008218, issued February, 1974.

US4008218
General References
Not Available
External Links
KEGG Compound
C01441
PubChem Compound
72392
PubChem Substance
46507306
ChemSpider
65325
BindingDB
8580
ChEBI
7489
ChEMBL
CHEMBL427409
Therapeutic Targets Database
DNC001004
HET
XXX
PDB Entries
2et8 / 2f4s / 2fcx

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP-2.9ALOGPS
logP-5.3ChemAxon
logS-0.5ALOGPS
pKa (Strongest Acidic)12.66ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area203.46 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity73.72 m3·mol-1ChemAxon
Polarizability32.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8567
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7666
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.7518
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8516
CYP450 2C9 substrateNon-substrate0.8033
CYP450 2D6 substrateNon-substrate0.8275
CYP450 3A4 substrateNon-substrate0.6391
CYP450 1A2 substrateNon-inhibitor0.9186
CYP450 2C9 inhibitorNon-inhibitor0.9257
CYP450 2D6 inhibitorNon-inhibitor0.9224
CYP450 2C19 inhibitorNon-inhibitor0.9062
CYP450 3A4 inhibitorNon-inhibitor0.9569
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.914
Ames testNon AMES toxic0.6928
CarcinogenicityNon-carcinogens0.952
BiodegradationNot ready biodegradable0.7421
Rat acute toxicity1.6749 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9779
hERG inhibition (predictor II)Non-inhibitor0.8599
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
2-deoxystreptamine aminoglycosides / O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / 1,2-aminoalcohols / Oxacyclic compounds / Acetals
show 3 more
Substituents
Amino cyclitol glycoside / 2-deoxystreptamine aminoglycoside / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Oxane / Monosaccharide
show 15 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
aminoglycoside, 2,6-dideoxy-alpha-D-glucoside (CHEBI:7489)

Drug created on September 11, 2007 11:49 / Updated on December 01, 2017 15:32